Table 3.
Cut‐off point1 | Sensitivity (%) | Specificity (%) | AUC (95% CI) | +LR2 | LR3 | P value (individually) | Coefficient (B) | P value (within model) | |
---|---|---|---|---|---|---|---|---|---|
CSF variables | |||||||||
FTLD (n = 90) vs. CON (n = 55) | |||||||||
MFG‐E8 | 5975 | 81 | 69 | 0.81 (0.734–0.884) | 2.61 | 0.28 | <0.0001 | −0.001 | <0.0001 |
tTau | 262.5 | 71 | 59 | 0.68 (0.592–0.765) | 1.73 | 0.49 | <0.0001 | 0.019 | <0.0001 |
Aβ 42 | 886 | 66 | 65 | 0.67 (0.577–0.755) | 1.89 | 0.52 | 0.001 | −0.003 | 0.008 |
FTLD vs. CON model | 0.594 | 88 | 85 | 0.93 (0.894–0.971) | 5.87 | 0.14 | <0.0001 | ||
FTLD (n = 91) vs. non‐FTLD dementia models (n = 37) | |||||||||
YKL40 | 273 | 72 | 70 | 0.74 (0.644–0.833) | 2.40 | 0.40 | <0.0001 | 0.011 | 0.001 |
pTau | 45.5 | 78 | 71 | 0.82 (0.729–0.911) | 2.69 | 0.31 | <0.0001 | −0.083 | <0.0001 |
p/tTau | 0.134 | 70 | 60 | 0.68 (0.577–0.788) | 1.75 | 0.50 | 0.001 | −13.04 | 0.017 |
Age | na | na | na | 0.55 (0.444–0.646) | na | na | 0.423 | −0.062 | 0.113 |
FTLD vs. non‐FTLD dementia model | 0.636 | 91 | 84 | 0.93 (0.884–0.975) | 5.69 | 0.11 | <0.0001 | ||
FTLD‐TDP (n = 42) vs. CON (n = 57) | |||||||||
YKL40 | 259.93 | 79 | 70 | 0.78 (0.690–0.881) | 2.63 | 0.30 | <0.0001 | 0.016 | <0.0001 |
MFG‐E8 | 6069.5 | 80 | 79 | 0.83 (0.745–0.907) | 3.81 | 0.25 | <0.0001 | −0.001 | <0.0001 |
Catalase | 4.44 | 70 | 62 | 0.71 (0.614–0.815) | 1.84 | 0.48 | <0.0001 | 0.413 | 0.151 |
TDP vs. CON model | 0.297 | 90 | 86 | 0.94 (0.898–0.989) | 6.43 | 0.12 | <0.0001 |
AUC, area under the curve; CI, confident interval; LR, likelihood ratio; CON, nondemented controls; FTLD, frontotemporal lobar degeneration, n.a, nonapplicable.
Selected value of the individual biomarker or combination where the two groups of analysis could be discriminated with the reported sensitivity and specificity.
Positive likelihood: sensitivity/100‐specificity.
Negative likelihood: 100‐sensitivity/specificity.
Markers/models achieving sufficient biomarker performance are highlighted in bold.